Phytochemicals as potential target on thioredoxin-interacting protein (TXNIP) for the treatment of cardiovascular diseases

被引:0
作者
Peng Zhou
Yao-yao Ma
Xiao-ni Zhao
Fang Hua
机构
[1] Anhui University of Chinese Medicine,Department of Integrated Traditional Chinese and Western Medicine
[2] Anhui Xinhua University,School of Pharmacy
来源
Inflammopharmacology | 2023年 / 31卷
关键词
Cardiovascular disease; TXNIP; Flavonoids; Phenols; Alkaloids; Molecular docking;
D O I
暂无
中图分类号
学科分类号
摘要
Cardiovascular diseases (CVDs) are currently the major cause of death and morbidity on a global scale. Thioredoxin-interacting protein (TXNIP) is a marker related to metabolism, oxidation, and inflammation induced in CVDs. The overexpression of TXNIP is closely related to the occurrence and development of CVDs. Hence, TXNIP inhibition is critical for reducing the overactivation of its downstream signaling pathway and, as a result, myocardial cell damage. Due to the chemical variety of dietary phytochemicals, they have garnered increased interest for CVDs prevention and therapy. Phytochemicals are a source of medicinal compounds for a variety of conditions, which aids in the development of effective and safe TXNIP-targeting medications. The objective of this article is to find and virtual screen novel safe, effective, and economically viable TXNIP inhibitors from flavonoids, phenols, and alkaloids derived from foods and plants. The results of the docking study revealed that silibinin, rutin, luteolin, baicalin, procyanidin B2, hesperetin, icariin, and tilianin in flavonoids, polydatin, resveratrol, and salidroside in phenols, and neferine in alkaloids had the highest Vina scores, indicating that these compounds are the active chemicals on TXNIP. In particular, silibinin can be utilized as a lead chemical in the process of structural alteration. These dietary phytochemicals may aid in the discovery of lead compounds for the development of innovative TXNIP agents for the treatment of cardiovascular disease.
引用
收藏
页码:207 / 220
页数:13
相关论文
共 50 条
  • [41] Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ
    Miligy, Islam M.
    Gorringe, Kylie L.
    Toss, Michael S.
    Al-Kawaz, Abdulbaqi A.
    Simpson, Peter
    Diez-Rodriguez, Maria
    Nolan, Christopher C.
    Ellis, Ian O.
    Green, Andrew R.
    Rakha, Emad A.
    MODERN PATHOLOGY, 2018, 31 (12) : 1807 - 1815
  • [42] Thioredoxin-interacting protein and myocardial mitochondrial function in ischemia-reperfusion injury
    Yoshioka, Jun
    Lee, Richard T.
    TRENDS IN CARDIOVASCULAR MEDICINE, 2014, 24 (02) : 75 - 80
  • [43] Targeting endothelial thioredoxin-interacting protein (TXNIP) protects from metabolic disorder-related impairment of vascular function and post-ischemic revascularisation
    Domingues, Alison
    Boisson-Vidal, Catherine
    Marquet de Rouge, Perrine
    Dizier, Blandine
    Sadoine, Jeremy
    Mignon, Virginie
    Vessieres, Emilie
    Henrion, Daniel
    Escriou, Virginie
    Bigey, Pascal
    Chaussain, Catherine
    Smadja, David M.
    Nivet-Antoine, Valerie
    ANGIOGENESIS, 2020, 23 (02) : 249 - 264
  • [44] A pan-cancer analysis of thioredoxin-interacting protein as an immunological and prognostic biomarker
    Xuxue Guo
    Mei Huang
    Haonan Zhang
    Qianhui Chen
    Ying Hu
    Yan Meng
    Changjie Wu
    Chenge Tu
    Yongfeng Liu
    Aimin Li
    Qingyuan Li
    Peirong Zhou
    Side Liu
    Cancer Cell International, 22
  • [45] A Critical Role for Thioredoxin-Interacting Protein in Diabetes-Related Impairment of Angiogenesis
    Dunn, Louise L.
    Simpson, Philippa J. L.
    Prosser, Hamish C.
    Lecce, Laura
    Yuen, Gloria S. C.
    Buckle, Andrew
    Sieveking, Daniel P.
    Vanags, Laura Z.
    Lim, Patrick R.
    Chow, Renee W. Y.
    Lam, Yuen Ting
    Clayton, Zoe
    Bao, Shisan
    Davies, Michael J.
    Stadler, Nadina
    Celermajer, David S.
    Stocker, Roland
    Bursill, Christina A.
    Cooke, John P.
    Ng, Martin K. C.
    DIABETES, 2014, 63 (02) : 675 - 687
  • [46] A pan-cancer analysis of thioredoxin-interacting protein as an immunological and prognostic biomarker
    Guo, Xuxue
    Huang, Mei
    Zhang, Haonan
    Chen, Qianhui
    Hu, Ying
    Meng, Yan
    Wu, Changjie
    Tu, Chenge
    Liu, Yongfeng
    Li, Aimin
    Li, Qingyuan
    Zhou, Peirong
    Liu, Side
    CANCER CELL INTERNATIONAL, 2022, 22 (01)
  • [47] The gene encoding thioredoxin-interacting protein (TXNIP) is a frequent virus integration site in virus-induced mouse leukemia and is overexpressed in a subset of AML patients
    Erkeland, Stefan J.
    Palande, Karishma K.
    Valkhof, Marijke
    Gits, Judith
    Danen-van Oorschot, Astrid
    Touw, Ivo P.
    LEUKEMIA RESEARCH, 2009, 33 (10) : 1367 - 1371
  • [48] Discovering the anti-diabetic potential of pomegranate peel metabolites by examining molecular interplay with the thioredoxin-interacting protein
    Aslam, Tahira
    Arif, Amina
    Arshad, Shafia
    Muccee, Fatima
    Ahmad, Khalil
    Iqbal, Muhammad Omer
    Khalil, Umair
    Razak, Suhail
    Afsar, Tayyaba
    Almajwal, Ali
    Shafique, Huma
    Zain, Maryam
    FRONTIERS IN MEDICINE, 2024, 10
  • [49] Targeting endothelial thioredoxin-interacting protein (TXNIP) protects from metabolic disorder-related impairment of vascular function and post-ischemic revascularisation
    Alison Domingues
    Catherine Boisson-Vidal
    Perrine Marquet de Rouge
    Blandine Dizier
    Jérémy Sadoine
    Virginie Mignon
    Emilie Vessières
    Daniel Henrion
    Virginie Escriou
    Pascal Bigey
    Catherine Chaussain
    David M. Smadja
    Valérie Nivet-Antoine
    Angiogenesis, 2020, 23 : 249 - 264
  • [50] Thioredoxin-interacting protein: a critical link between autophagy disorders and pancreatic β-cell dysfunction
    Deng, Wenzhen
    Li, Yang
    Ren, Ziyu
    He, Qirui
    Jia, Yanjun
    Liu, Yongjian
    Zhang, Weiwei
    Gan, Xianfeng
    Liu, Dongfang
    ENDOCRINE, 2020, 70 (03) : 526 - 537